NAS:DNLI (USA) Also trade in: Germany

Denali Therapeutics Inc

$ 20.77 -0.35 (-1.66%)
Volume: 280,245 Avg Vol (1m): 437,364
Market Cap $: 1.98 Bil Enterprise Value $: 1.50 Bil
P/E (TTM): 0.00 P/B: 3.81
Earnings Power Value 0
Net Current Asset Value 3.58
Tangible Book 5.44
Projected FCF 0
Median P/S Value 710.3
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
59.93% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
DNLI: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.76
Equity-to-Asset ranked higher than
77.46% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
DNLI: 0.76
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.76, Med: 0.85, Max: 0.88
Current: 0.76
0.76
0.88
Interest Coverage No Debt
Interest Coverage ranked higher than
50.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
DNLI: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Altman Z-Score 7.54
DISTRESS
GREY
SAFE

Profitability & Growth : 1/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -47.57
Operating Margin ranked lower than
88.89% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
DNLI: -47.57
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -47.57, Med: -35.9, Max: -35.9
Current: -47.57
-47.57
-35.9
Net Margin % -38.84
Net Margin ranked lower than
88.89% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
DNLI: -38.84
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -38.84, Med: -28.06, Max: -28.06
Current: -38.84
-38.84
-28.06
ROE % -10.09
ROE ranked higher than
52.98% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
DNLI: -10.09
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -47.46, Med: -27.31, Max: -7.16
Current: -10.09
-47.46
-7.16
ROA % -8.40
ROA ranked higher than
51.38% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
DNLI: -8.4
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -56.31, Med: -34.52, Max: -6.31
Current: -8.4
-56.31
-6.31
ROC (Joel Greenblatt) % -296.27
ROC (Joel Greenblatt) ranked lower than
59.94% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
DNLI: -296.27
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -948.81, Med: -561.87, Max: -231.37
Current: -296.27
-948.81
-231.37
3-Year Total EBITDA Growth Rate -33.00
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
DNLI: 57.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate 58.80
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
DNLI: 58.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» DNLI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:DNLI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare LSE:GNS XMCE:ALM ROCO:4147 NAS:PTLA NYSE:XON SZSE:300294 XKRX:006280 NAS:CORT SZSE:002287 NAS:AKCA SZSE:002653 NAS:SGMO NAS:ESPR NAS:RXDX NAS:MYOK NAS:XLRN NAS:EDIT XKRX:095700 NAS:SPPI NYSE:CBM
Traded in other countries 4DN.Germany
Address 151 Oyster Point Boulevard, 2nd Floor, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others.

Ratios

Current vs industry vs history
PB Ratio 3.81
PB Ratio ranked higher than
63.10% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
DNLI: 3.81
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.4, Med: 3.54, Max: 5.13
Current: 3.81
2.4
5.13
PS Ratio 14.75
PS Ratio ranked lower than
94.77% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
DNLI: 14.75
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 13.23, Med: 504.84, Max: 3227.14
Current: 14.75
13.23
3227.14
EV-to-EBIT -23.68
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
DNLI: -23.68
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -34.4, Med: -14.65, Max: -6.2
Current: -23.68
-34.4
-6.2
EV-to-EBITDA -27.66
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
DNLI: -27.66
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -41, Med: -15.15, Max: -6.4
Current: -27.66
-41
-6.4
EV-to-Revenue 11.30
EV-to-Revenue ranked lower than
90.66% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
DNLI: 11.3
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 9.6, Med: 390.25, Max: 2573.8
Current: 11.3
9.6
2573.8
Current Ratio 11.55
Current Ratio ranked higher than
81.28% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
DNLI: 11.55
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 9.6, Med: 14.67, Max: 28.92
Current: 11.55
9.6
28.92
Quick Ratio 11.55
Quick Ratio ranked higher than
81.84% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
DNLI: 11.55
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 9.6, Med: 14.67, Max: 28.92
Current: 11.55
9.6
28.92
Days Sales Outstanding 20.25
Days Sales Outstanding ranked lower than
100.00% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
DNLI: 20.25
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 20.25, Med: 20.81, Max: 20.81
Current: 20.25
20.25
20.81

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -213.50
3-Year Share Buyback Rate ranked lower than
100.00% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
DNLI: -213.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.82
Price-to-Tangible-Book ranked higher than
70.36% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
DNLI: 3.82
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.9, Med: 3.51, Max: 4.43
Current: 3.82
2.9
4.43
Price-to-Median-PS-Value 0.03
Price-to-Median-PS-Value ranked higher than
90.27% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
DNLI: 0.03
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 1.13, Max: 5.56
Current: 0.03
0.03
5.56
Earnings Yield (Joel Greenblatt) % -4.17
Earnings Yield (Greenblatt) ranked lower than
59.67% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
DNLI: -4.17
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -16.1, Med: -6.85, Max: -2.9
Current: -4.17
-16.1
-2.9

More Statistics

Revenue (TTM) (Mil) $ 132.72
EPS (TTM) $ -0.59
Beta 0
Volatility % 82.77
52-Week Range $ 12.32 - 28.87
Shares Outstanding (Mil) 95.48

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N